ERBB2 and breast carcinoma: In conclusion, the real-world data demonstrate similar efficacy and safety for HLX02 and RTZ, both combined with pertuzumab and various chemotherapy regimens, as the first-line treatment for HER2-positive advanced breast cancer patients in China.